摘要
目的研究头孢哌酮舒巴坦+吸入用乙酰半胱氨酸运用于反复加重的支气管扩张症患者中的价值。方法选择洛阳伊洛医院2020年1月至2021年10月纳入的68例支气管扩张症患者,通过随机数字表法分为两组,研究组34例采取头孢哌酮舒巴坦+乙酰半胱氨酸,对照组34例采取乙酰半胱氨酸。比较两组药物治疗2周后的治疗有效率、服药前后的最大呼气流量(PEF)、第1 s用力呼气容积(FEV1)、用力肺活量(FVC)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、咳痰量、咳嗽症状、呼吸困难(mMRC)、不良反应、二氧化碳分压(PaCO_(2))、血氧分压(PaO_(2))、血氧饱和度(SaO_(2))、症状积分。结果研究组治疗有效率(91.18%)大于对照组(67.65%),差异有统计学意义(P<0.05)。两组服药前的肺功能[最大呼气流量(PEF)、第1 s用力呼气容积(FEV1)、用力肺活量(FVC)]差异无统计学意义(P>0.05),研究组服药后的PEF、FEV1、FVC均大于对照组,差异有统计学意义(P<0.05)。两组服药前的炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]差异无统计学意义(P>0.05),研究组服药后的TNF-α、IL-6、IL-8均小于对照组,差异有统计学意义(P<0.05)。两组服药前的病情差异无统计学意义(P>0.05),研究组服药后的咳痰量、咳嗽症状、mMRC评分均小于对照组,差异有统计学意义(P<0.05)。研究组不良反应(11.76%)与对照组(20.59%)差异无统计学意义(P>0.05)。两组服药前的血气指标[二氧化碳分压(PaCO_(2))、血氧分压(PaO_(2))、血氧饱和度(SaO_(2))]差异无统计学意义(P>0.05),研究组服药后的PaCO_(2)小于对照组,PaO_(2)、SaO_(2)大于对照组,差异有统计学意义(P<0.05)。两组服药前的症状积分差异无统计学意义(P>0.05),研究组服药后的积分均小于对照组,差异有统计学意义(P<0.05)。结论头孢哌酮舒巴坦+吸入用乙酰半胱氨酸的疗效更为理想,增强肺功能,可促进炎性反应消失,减少咳痰量,不良反应少,改善血气指标,使症状快速减轻,安全性较高。
Objective To study the clinical value of sulbactam and cefopcrazone combined with inhaled acetylcysteine in patients with recurrent bronchiectasis.Methods A total of 68 patients with bronchiectasis enrolled in Luoyang Yiluo Hospital from January 2020 to October 2021 were selected and divided into two groups by random number table method.The study group(N=34)received cefoperazone sulbactam+acetylcysteine,while the control group(N=34)received acetylcysteine.The effective rate,maximal expiratory flow(PEF),forced expiratory volume in one second(FEV1),forced vital capacity(FVC),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-8(IL-8),expectoration volume,cough symptoms,modified medical research council scale(mMRC),adverse reactions,partial pressure of carbon dioxide(PaCO_(2)),partial pressure of oxygen(PaO_(2)),blood oxygen saturation(SaO_(2)),clinical symptom score were compared between the two groups after 2 weeks of drug treatment.Results The effective rate of the study group(91.18%)was higher than that of the control group(67.65%),and the difference was statistically significant(P<0.05).There was no significant difference in pulmonary function[maximum expiratory flow(PEF),forced expiratory volume(FEV1),and forced vital capacity(FVC)]between the two groups before taking medicine(P>0.05).The PEF,FEV1,and FVC in the study group were higher than those in the control group after taking medicine,and the differences were statistically significant(P<0.05).There was no significant difference in inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and interleukin-8(IL-8)]between the two groups before taking medicine(P>0.05).The levels of TNF-α,IL-6,and IL-8 in the study group were lower than those in the control group after taking medicine,and the differences were statistically significant(P<0.05).There was no significant difference in the disease condition between the two groups before taking medicine(P>0.05).The sputum production volume,cough symptoms and mMRC score of the study group were lower than those of the control group after taking medicine,and the differences were statistically significant(P<0.05).There was no significant difference in adverse reactions between the study group(11.76%)and the control group(20.59%)(P>0.05).There was no significant difference in blood gas indexes[partial pressure of carbon dioxide(PaCO_(2)),partial pressure of oxygen(PaO_(2)),blood oxygen saturation(SaO_(2))]between the two groups before taking medicine(P>0.05).After taking medicine,the PaCO_(2) of the study group was lower than that of the control group,and the PaO_(2) and SaO_(2) were higher than that of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in symptom scores between the two groups before taking medicine(P>0.05),but the score of the study group was lower than that of the control group after taking medicine(P<0.05).Conclusion Cefoperazone sulbactam+inhaled acetylcysteine has a more ideal curative effect,which can enhance lung function,promote the disappearance of inflammatory reactions,reduce sputum production,reduce adverse reactions,improve blood gas indicators,reduce symptoms quickly,and have high safety.
作者
李贺梅
LI Hemei(Department of Respiratory and Critical Care Medicine,Luoyang Yiluo Hospital,Luoyang Henan 471000,China)
出处
《临床研究》
2022年第11期60-63,共4页
Clinical Research
作者简介
李贺梅(1985—),女,汉族,洛阳偃师人,主治医师,本科。研究方向:呼吸道感染疾病的诊治方面。
